Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00963053 · ClinicalTrials.gov registry record · Phase 2
VA111913 Dysmenorrhoea Efficacy and Safety Proof of Concept
A Phase 2 study of Primary Dysmenorrhea, sponsored by Vantia.
- Completed
- Registry status
- Phase 2
- Development phase
- 146
- Enrollment target
- 4
- Study locations
NCT00963053: Completed Phase 2 study of Primary Dysmenorrhea, sponsored by Vantia.
NCT00963053 is a Phase 2 study of Primary Dysmenorrhea that has completed, run by Vantia. The registered enrollment target is 146 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (10% higher). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00963053, a Phase 2 study of Primary Dysmenorrhea, has completed, sponsored by Vantia.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 146 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of the study is to investigate how effective VA111913 is at preventing menstrual pain in women with primary dysmenorrhoea.
Conditions Studied
Interventions
- DRUG VA111913 TS and placebo
Study Locations (4)
Arizona
- Pivotal Research Centers - Peoria
Texas
- Premier Research Group - Austin
Utah
- Jean Brown Research - Salt Lake City
Other
- Bio-Kinetic Europe Limited - Belfast
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 146 participants |
| Start Date | 2009-08 |
| Est. Completion | 2010-11 |
| Phase | Phase 2 |
What the finished NCT00963053 record still lists
NCT00963053 is an interventional study that assigns participants to a tested intervention. The registered 146 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (10% higher).
The record links to 1 condition, with Primary Dysmenorrhea appearing as the primary indexed condition, and to 1 intervention - of which VA111913 TS and placebo is the first listed.
NCT00963053 reports a single indexed study location in Arizona, Texas, Utah.
Frequently Asked Questions
What is clinical trial NCT00963053 about?
NCT00963053 is a clinical study titled "VA111913 Dysmenorrhoea Efficacy and Safety Proof of Concept". The purpose of the study is to investigate how effective VA111913 is at preventing menstrual pain in women with primary dysmenorrhoea.
What is the current status of trial NCT00963053?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 146 participants. The study started on 2009-08. Estimated completion is 2010-11.
What conditions does trial NCT00963053 study?
This clinical trial studies the following conditions: Primary Dysmenorrhea.
What interventions are being tested in trial NCT00963053?
The interventions under investigation include: VA111913 TS and placebo (DRUG).
Who is sponsoring clinical trial NCT00963053?
This trial is sponsored by Vantia, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00963053 being conducted?
This trial has 4 study locations across Arizona, Texas, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Primary Dysmenorrhea
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00963053's enrollment target sits among peer trials
146 496th of 2000 higher than 1,503 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03490929 · 146 participants · Phase 4
CEUS for Blunt Abdominal Trauma in Children
- NCT04755062 · 146 participants · NA
A Culturally-relevant Micronutrient-dense Plant-rich (mNDPR) Dietary Intervention for Native Americans
- NCT04867954 · 146 participants
Development of 4D Flow MRI for Risk Stratification of Variceal Bleeding in Cirrhosis
- NCT05051618 · 146 participants · NA
Exercise Training for Managing Major Depressive Disorder in Multiple Sclerosis
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia